Paul Choi
Stock Analyst at Goldman Sachs
(3.30)
# 1,024
Out of 4,711 analysts
94
Total ratings
51.61%
Success rate
1.93%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LNTH Lantheus Holdings | Initiates: Buy | $143 | $89.29 | +60.16% | 1 | Dec 18, 2024 | |
| ESPR Esperion Therapeutics | Reinstates: Neutral | $4 | $2.19 | +82.65% | 8 | Dec 18, 2024 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $42 | $46.24 | -9.17% | 7 | Dec 4, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $180 → $200 | $136.38 | +46.65% | 3 | Sep 17, 2024 | |
| CYTK Cytokinetics | Downgrades: Neutral | $85 → $60 | $48.87 | +22.77% | 2 | Aug 13, 2024 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $12 | $7.45 | +61.07% | 7 | Aug 9, 2024 | |
| DVAX Dynavax Technologies | Maintains: Neutral | $20 → $15 | $12.72 | +17.92% | 2 | Aug 8, 2024 | |
| HCM HUTCHMED (China) | Maintains: Neutral | $17 → $19 | $14.31 | +32.77% | 6 | Aug 1, 2024 | |
| GOSS Gossamer Bio | Maintains: Buy | $8 | $0.84 | +852.38% | 4 | Jun 17, 2024 | |
| RGNX REGENXBIO | Initiates: Buy | $38 | $7.62 | +398.69% | 1 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $18.48 | +278.79% | 1 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $18 | $10.64 | +69.17% | 2 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $20.59 | +55.42% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $28 | $7.34 | +281.47% | 7 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $1.5 → $1 | $0.46 | +117.39% | 7 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $26.49 | +88.75% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.14 | +269.65% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $2 | $0.40 | +400.00% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $38.63 | +55.32% | 1 | Dec 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.50 | +1,566.67% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $4 | $1.20 | +233.33% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $36.26 | +368.84% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $2.75 | +190.91% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $15.52 | +112.63% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $35.59 | +214.70% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $135.42 | -0.31% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $18 → $20 | $0.93 | +2,054.48% | 2 | Mar 30, 2020 |
Lantheus Holdings
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $89.29
Upside: +60.16%
Esperion Therapeutics
Dec 18, 2024
Reinstates: Neutral
Price Target: $4
Current: $2.19
Upside: +82.65%
PTC Therapeutics
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $46.24
Upside: -9.17%
Ascendis Pharma
Sep 17, 2024
Maintains: Buy
Price Target: $180 → $200
Current: $136.38
Upside: +46.65%
Cytokinetics
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $48.87
Upside: +22.77%
Phathom Pharmaceuticals
Aug 9, 2024
Maintains: Neutral
Price Target: $10 → $12
Current: $7.45
Upside: +61.07%
Dynavax Technologies
Aug 8, 2024
Maintains: Neutral
Price Target: $20 → $15
Current: $12.72
Upside: +17.92%
HUTCHMED (China)
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $14.31
Upside: +32.77%
Gossamer Bio
Jun 17, 2024
Maintains: Buy
Price Target: $8
Current: $0.84
Upside: +852.38%
REGENXBIO
Jun 7, 2024
Initiates: Buy
Price Target: $38
Current: $7.62
Upside: +398.69%
Feb 1, 2024
Initiates: Buy
Price Target: $70
Current: $18.48
Upside: +278.79%
Jul 31, 2023
Maintains: Neutral
Price Target: $11 → $18
Current: $10.64
Upside: +69.17%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $20.59
Upside: +55.42%
Jul 21, 2023
Maintains: Buy
Price Target: $51 → $28
Current: $7.34
Upside: +281.47%
Jul 20, 2023
Maintains: Sell
Price Target: $1.5 → $1
Current: $0.46
Upside: +117.39%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $26.49
Upside: +88.75%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.14
Upside: +269.65%
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $0.40
Upside: +400.00%
Dec 14, 2022
Initiates: Buy
Price Target: $60
Current: $38.63
Upside: +55.32%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.50
Upside: +1,566.67%
May 24, 2022
Maintains: Neutral
Price Target: $10 → $4
Current: $1.20
Upside: +233.33%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $36.26
Upside: +368.84%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $2.75
Upside: +190.91%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $15.52
Upside: +112.63%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $35.59
Upside: +214.70%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $135.42
Upside: -0.31%
Mar 30, 2020
Upgrades: Neutral
Price Target: $18 → $20
Current: $0.93
Upside: +2,054.48%